<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05794165</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-22-1102</org_study_id>
    <nct_id>NCT05794165</nct_id>
  </id_info>
  <brief_title>Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism</brief_title>
  <acronym>TRAIT</acronym>
  <official_title>Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism (TRAIT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if additional interventions will assist with&#xD;
      decreasing the risk and/or severity of thromboembolism (clotting complications) in patients&#xD;
      who have experienced a major traumatic event.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2023</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-center, placebo-controlled, randomized, double-blind study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This will be a double-blind study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with incidences of venous thromboembolism (VTE )</measure>
    <time_frame>14 days post hospital admission</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with incidence of antifactor Xa (anti-FXa) of ≥0.2 IU/mL</measure>
    <time_frame>14 days post hospital admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time taken to achieve anti-FXa of ≥0.2 IU/mL</measure>
    <time_frame>14 days post hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of enoxaparin dose escalations</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidences of participants with other thrombotic complications (arterial thrombosis, myocardial infarction, stroke)</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidences of participants with bleeding events (interoperative bleeding, abdominal bleeding)</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital free days</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Ventilator free days</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU free days</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Anti-FXa</measure>
    <time_frame>from the time of hospital admission up to hospital day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antithrombin (AT) activity level</measure>
    <time_frame>from the time of hospital admission up to hospital day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of the endothelial marker syndecan-1 as assessed by a blood test</measure>
    <time_frame>time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of the endothelial marker thrombomodulin as assessed by a blood test</measure>
    <time_frame>From the time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Tumor necrosis factor alpha (TNFα) as assessed by a blood test</measure>
    <time_frame>From time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Interleukin-8 (IL-8) as assessed by a blood test</measure>
    <time_frame>From time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Interleukin-6(IL-6) as assessed by a blood test</measure>
    <time_frame>time of hospital admission, day1, day2, day 3, day 4, day 5, day6, day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Interleukin-1 beta (IL1b) as assessed by a blood test</measure>
    <time_frame>From time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Interleukin-1 alpha (IL1a) as assessed by a blood test</measure>
    <time_frame>From time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in level of Inflammatory marker Interferon -gamma (INFg) as assessed by a blood test</measure>
    <time_frame>From time of hospital admission to day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with In-hospital mortality</measure>
    <time_frame>from the time of hospital admission to the time of hospital discharge or 30 days (whichever occurs first)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Trauma Injury</condition>
  <condition>Thromboembolism</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Thrombate infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thrombate infusion</intervention_name>
    <description>Bolus intravenous infusion of Thrombate will be given to achieve antithrombin (AT) activity levels at 150% after the 3rd dose of Enoxaparin. The dose will be based on patient weight.</description>
    <arm_group_label>Thrombate infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal Saline will be given as one time IV after the 3rd dose of Enoxaparin. The dose will be based on patient weight.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Highest level of trauma activation or upgrade to highest level&#xD;
&#xD;
          -  Polytraumatic injuries OR pelvic/long bone fracture&#xD;
&#xD;
          -  Admission to trauma ICU or Surgical Intermediate Care Unit (SIMU)&#xD;
&#xD;
          -  Informed consent obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prisoners (defined as those directly admitted from correctional facility)&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  ≥ 20% total body surface area (TBSA) burned&#xD;
&#xD;
          -  Nonsurvivable head injuries&#xD;
&#xD;
          -  Known hematologic or immunologic disorders&#xD;
&#xD;
          -  Known prehospital anticoagulant use&#xD;
&#xD;
          -  Patients initially placed on unfractionated heparin for thromboprophylaxis&#xD;
&#xD;
          -  Known allergy to Antithrombin or it's components&#xD;
&#xD;
          -  Enrollment in another interventional study unless approved by Trial Principal&#xD;
             Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan A Cotton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan A Cotton, MD</last_name>
    <phone>713-500-7187</phone>
    <email>Bryan.A.Cotton@uth.tmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeanette M Podbielski</last_name>
    <phone>832-656-9797</phone>
    <email>Jeanette.M.Podbielski@uth.tmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Bryan A Cotton, MD</last_name>
      <phone>713-500-7187</phone>
      <email>Bryan.A.Cotton@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette M Podbielski</last_name>
      <phone>832-656-9797</phone>
      <email>Jeanette.M.Podbielski@uth.tmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 14, 2023</study_first_submitted>
  <study_first_submitted_qc>March 28, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 28, 2023</last_update_submitted>
  <last_update_submitted_qc>March 28, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Bryan Cotton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

